CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 300 enrolled
Drug / intervention
ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00684138
NCT00684138Phase 4Completed
CompareCT.gov

ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens (IOL)

Alcon Research·interventional·Posted May 26, 2008·Updated Jul 13, 2010

In Brief

A Phase 4 clinical trial evaluating ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens and ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens for Cataract. Completed, enrolled 300 participants across 1 site.

Detailed Summary

Randomized, parallel group, subject masked, multi-center six (6) month follow-up study comparing ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power IOL Model SN6AD1 implanted in both eyes to ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power IOL Model SN6AD3 implanted in both eyes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 26, 2008
Enrollment StartJun 1, 2007
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 18.1 years ago

Interventions

ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lensdevice

Intraocular Lens

ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lensdevice

Intraocular Lens